Catalyze B.V.

Their core work

Catalyze B.V. is a Netherlands-based SME that provides specialized support services for health research projects, likely in areas such as clinical research management, health economics evaluation, and patient engagement strategies. Their involvement across diverse clinical domains — from cardiac arrest prevention to spinal regeneration to multimorbidity management — indicates they contribute cross-cutting expertise rather than disease-specific research. The company appears to offer methodological and operational capabilities that research consortia need to translate clinical science into practical healthcare solutions. Their consistent participant role across varied health topics suggests a service-oriented model supporting clinical trials, data management, or health technology assessment.

What they specialise in

How they've shifted over time

In their early H2020 period (2017-2019), Catalyze engaged in foundational biomedical research — genetic epidemiology of cardiac arrest (ESCAPE-NET) and stem cell-based regenerative medicine (iPSpine). Their later projects (2020-2021) shifted markedly toward clinical implementation and patient-centered care, with PROFID developing clinical decision tools for post-myocardial infarction patients and EHRA-PATHS tackling multimorbidity management through integrated care pathways. This evolution signals a move from supporting basic research toward health systems optimization and personalized prevention.

Catalyze is moving toward implementation science and patient-centered health system design, making them increasingly relevant for projects bridging clinical research and real-world healthcare delivery.

How they like to work

Catalyze operates exclusively as a consortium participant, never leading projects, which is consistent with a service-provider model where they contribute specific expertise to researcher-led initiatives. With 75 unique partners across 19 countries from just 4 projects, they work in large, international consortia — their average consortium has nearly 20 partners. This broad network exposure without repeated partnerships suggests they are adaptable collaborators who bring portable skills to different research teams rather than relying on established relationships.

Despite only four projects, Catalyze has built connections with 75 distinct partners across 19 countries, reflecting participation in large pan-European health research consortia. Their network spans most of the EU, with no apparent geographic concentration beyond their Netherlands base.

What sets them apart

Catalyze occupies a niche as an SME that bridges multiple health research domains with transferable methodological expertise — few small companies can contribute meaningfully to projects ranging from stem cell therapy to cardiac epidemiology to elderly multimorbidity care. Their versatility across clinical topics suggests they bring process expertise (trial support, health economics, data management) rather than competing on scientific specialization. For consortium builders, this makes them a flexible partner who can handle operational complexity in health-focused projects without domain lock-in.

Highlights from their portfolio

• EHRA-PATHS
  Largest funding (€291,562) and most recent project, reflecting their evolution toward integrated care for multimorbid elderly patients with atrial fibrillation.
• iPSpine
  Stands out as a regenerative medicine project using induced pluripotent stem cells, showing Catalyze's range beyond their cardiovascular core.
• ESCAPE-NET
  Their earliest H2020 project, building a European cardiac arrest database — foundational work that connects to their later cardiac prevention projects.